Loading
Life sciences · Journal article
Pharmaceuticals · October 25, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Antimicrobial resistance (AMR) in ESKAPE pathogens represents a major threat to infectious disease therapy and has stimulated interest in metal-based antibacterial agents as complements or alternatives to conventional organic antibiotics. Their diverse coordination geometries, tunable redox properties, ligand-exchange behaviour, and capacity to interact with multiple biological targets offer distinctive opportunities for antibacterial drug development. However, despite the potent in vitro activity reported for numerous compounds, progression towards clinical application remains limited. This critical narrative review evaluates the evidence on chemical identity and speciation, causal mechanisms, and pharmacological exposure required to advance metal-based antibacterial candidates towards clinical translation, using gold, bismuth, gallium, copper, silver, and ruthenium compounds as comparative case studies. Three recurrent limitations are identified: insufficient characterisation of metal-complex speciation under biologically relevant conditions; reliance on minimum inhibitory concentration (MIC) measurements and indirect assays to infer molecular targets or causal mechanisms without rigorous validation; and the scarcity and poor integration of pharmacokinetic, safety, and in vivo efficacy data. The available evidence reveals compound-specific advances, including the repurposing potential of auranofin, bismuth-mediated inhibition of New Delhi metallo-β-lactamase 1 (NDM-1), and the clinical evaluation of gallium nitrate in chronic Pseudomonas aeruginosa airway infection in people with cystic fibrosis. Nevertheless, these findings cannot be extrapolated to entire metal classes. The review translates these gaps into four research priorities and candidate-progression criteria to guide experimental design and decisions to advance, reformulate, or discontinue candidate development.